Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Buys UCB Unit
by Lisa M. Jarvis
February 2, 2009
| A version of this story appeared in
Volume 87, Issue 5
GlaxoSmithKline will pay $680 million in cash for the commercial operations and distribution rights for UCB's marketed product portfolio in certain parts of Africa, the Middle East, Asia-Pacific, and Latin America. The deal gives GSK rights to sell the epilepsy drug Keppra and the allergy drugs Xyzal and Zyrtec, among other drugs. It also ties into GSK's recently launched strategy to strengthen its position in emerging markets, which the company says will represent 40% of growth in pharmaceuticals by 2020, in order to reduce its reliance on blockbuster drugs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter